Background. Factors involved in the development of resistance to sulphadoxine-pyrimethamine (SP) by Plasmodium falciparum, particularly in the context of intermittent preventive treatment during pregnancy (IPTp), are not well known. We aimed to determine the impact of IPTp and human immunodeficiency virus (HIV) infection on molecular markers of SP resistance and the clinical relevance of resistant infections.
Background. Factors involved in the development of resistance to sulphadoxine-pyrimethamine (SP) by Plasmodium falciparum, particularly in the context of intermittent preventive treatment during pregnancy (IPTp), are not well known. We aimed to determine the impact of IPTp and human immunodeficiency virus (HIV) infection on molecular markers of SP resistance and the clinical relevance of resistant infections.
Methods. SP resistance alleles were determined in peripheral (n 5 125) and placental (n 5 145) P. falciparum isolates obtained from pregnant women enrolled in a randomized, placebo-controlled trial of IPTp in Manhic xa, Mozambique.
Results. Prevalence of quintuple mutant infections was 12% (23 of 185 isolates) in pregnant women who received placebo and 24% (20 of 85 isolates) in those who received SP (P 5 .031). When the last IPTp dose was administered at late pregnancy, mutant infections at delivery were more prevalent in placental samples (7 No association was found between mutant infections and increased parasite density or malaria-related morbidity in mothers and children.
Conclusions. IPTp with SP increases the prevalence of resistance markers in the placenta and in HIV-infected women at delivery, which suggests that host immunity is key for the clearance of drug-resistant infections. However, this effect of IPTp is limited to the period when blood levels of SP are likely to be significant and does not translate into more-severe infections or adverse clinical outcomes.
Prompt diagnosis and effective treatment of malaria episodes are recommended for the control of malaria throughout the tropics. However, the success of Plasmodium falciparum treatment with antimalarials is compromised by drug resistance and the lack of alternative drugs. The threat of antimalarial resistance is even greater for pregnant women because of their increased risk of malaria [1] and the limited availability of antimalarial drugs that have been proven safe and effective in pregnancy [2] . Moreover, pregnancy entails physiological changes that can alter drug disposition and metabolism [3] , particularly in the placenta, where parasites accumulate to high densities [4] . Also, conditions known to impair maternal immunity, such as human immunodeficiency virus (HIV) co-infection [5] , may alter the efficacy of antimalarials, which depends not only on the susceptibility of the parasite but also, importantly, on host immunity [6] .
Although sulphadoxine-pyrimethamine (SP) is not currently used for first-line malaria treatment because of its low therapeutic efficacy, it is provided to pregnant women in most African countries as intermittent preventive treatment (IPTp). This intervention has shown considerable benefits to the mother and the fetus [7, 8] . However, the use of slowly eliminated SP [9] inherently risks increasing drug resistance, which is acquired through the stepwise accumulation of point mutations in the parasite genes encoding the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) enzymes of the folate metabolism [10] . Quintuple mutations in dhfr-51, -59, and -108 and dhps-437 and -540 codons confer high levels of drug resistance in vitro [11] . Although chemoprophylaxis of malaria in pregnancy with pyrimethamine has been associated with the selection of dhfr triple mutations in the placenta [12] , self-reported use of IPTp at the same study site [13] did not increase the prevalence of resistant alleles. Observational studies in other settings support this finding [14] . In contrast, a recent study showed an increased fraction of mutant parasites among women who self-reported IPTp use [15] . Moreover, contradictory results about the impact of mutant infections on pregnancy outcomes have been reported [12, 15] .
To understand the potential contribution of mutated parasites to malaria-related morbidity in mothers and children and the mechanisms underlying the emergence of drug resistance, we aimed to assess the impact of IPTp and maternal HIV infection on the prevalence of molecular markers of SP resistance. To address this, we analyzed P. falciparum isolates collected at delivery from Mozambican pregnant women participating in a randomized, double-blind, placebo-controlled trial of IPTp with SP.
MATERIAL AND METHODS

Study Area and Population
The study was conducted at the Centro de Investigac xão em Saú de da Manhic xa (CISM) in Manhic xa District of southern Mozambique during the period 2003-2005, before IPTp-SP was recommended by the Ministry of Health. In this area, perennial malaria transmission with some seasonality is mostly attributable to P. falciparum [16] , and the estimated entomological inoculation rate for 2002 was 38 infective bites per person per year. During the study, malaria control in pregnancy relied exclusively on case management with chloroquine (CQ) plus SP for cases of uncomplicated malaria (in the first trimester CQ alone was given). At that time, highly active antiretroviral therapy was not available, and national policy on prevention of mother-to-child transmission of HIV infection was selfadministration of nevirapine to the mother at the onset of labor and to the newborn within the first 72 h of life [17] .
Study Design
This study was done in the context of a randomized, doubleblind, placebo-controlled trial of IPTp with SP (trial registration number: NCT00209781) [17] . Pregnant women were enrolled into the study if they agreed to participate and signed the informed consent form. If their gestational age was <28 weeks, pregnant women received a long-lasting insecticide-treated net and were randomized to receive SP or placebo twice from the second trimester, at least 1 month apart. At delivery, birth weight was measured and blood samples were collected from the placenta, cord, and periphery of the mothers for hematological and parasitological examination. Impression smear and placental biopsy specimens were collected from the maternal side of the placentas for histological examination. Peripheral and placental blood samples were also collected onto filter papers (Schleicher & Schuell number 903TM). Hematocrit levels of the mothers and their children were measured 1 month after delivery, and clinical malaria episodes in women until 8 weeks postpartum and in infants during the first year of life were recorded through passive detection of cases reported at the Manhic xa outpatient clinic.
Filter papers corresponding to blood samples from pregnant women of known HIV status and a peripheral microscopic P. falciparum infection (n 5 86) or a histological-confirmed placental active infection (defined as the presence of parasites alone or together with pigment; n 5 104) were included in the study. Also, an HIV-stratified random selection of 350 paired peripheral-placental blood samples from slide-negative pregnant women was included for the analysis of submicroscopic infections. The study was approved by the national Mozambican ethics review committee and the Hospital Clínic of Barcelona ethics review committee.
Laboratory Methods
Thin and thick films, impression smears, and placental biopsy specimens were read according to standard, quality-controlled procedures [18, 19] . Hematocrit levels were measured in a microcapillary tube after centrifugation. Maternal HIV type 1 status was determined with the Determine HIV-1/2 Rapid Test (Abbott Laboratories) and was confirmed with the Unigold rapid test (Trinity Biotech) [17] .
DNA was extracted from a drop of 50 lL of blood onto filter paper with an ABIPrism 6700 Automated Nucleic Acid Work Station (Applied Biosystems) and resuspended into a final volume of 200 lL of water. Five microliters of the DNA extracts were screened for P. falciparum DNA by real-time quantitative polymerase chain reaction (qPCR) [20] . Parasitemia was quantified using the ABI Prism SDS2.1 software by extrapolation of cycle thresholds from a standard curve of known numbers of ring-infected erythrocytes diluted in whole blood. A negative control sample with no template DNA was also run in all reactions.
P. falciparum dhfr-51, -59, and -108 and dhps-437 and -540 genotypes were determined by restriction fragment-length polymorphism analysis of amplicons generated by nested PCR and electrophoresis on agarose gels [21] . Multiplicity of infection (MOI) was determined as the highest number of msp-1 or msp-2 PCR products detected in the sample [22] . Molecular analysis was blinded to origin of the sample (placental or peripheral), treatment group allocation (SP or placebo), and HIV status.
Definitions and Statistical Analysis
Infections were defined as pure quintuple mutants (q-mutants) if all 5 dhfr/dhps mutations were detected and there was no evidence of any wild-type parasite. Pregnant women were classified into first-time mothers (primigravidae; PG) and those with at least 1 previous pregnancy (multigravidae; MG). Age was stratified as <20, 21-25 and .25 years. Placental inflammation was defined by .5 inflammatory cells seen by histological examination in 10 high-power fields (original magnification, 3400). Late IPTp treatment was defined when pregnant women received the last SP dose within 2.5 months before delivery (median period of time between last SP dose and delivery among the women participating in the study; interquartile range, 1.9-3.4 months) and early-IPTp treatment if the interval between last SP dose and delivery was .2.5 months. Statistical analysis was performed using Stata software, version 11.0 (StataCorp). Proportions and log-transformed parasite densities were compared by Fisher's exact test and Student's t test, respectively. McNemar's test was used to compare prevalences of q-mutants among paired placental and peripheral samples. Logistic regression models were estimated to evaluate the association of qmutants with early and late-IPTp, placental inflammation, parity, age, and HIV infection. Linear models were used to estimate the association of q-mutants with log-transformed parasite densities, MOI, newborn weight, and hematocrit levels in mothers, cords, and infants. Poisson regression models were used to evaluate the association of q-mutants with the number of malaria episodes in mothers during the postpartum period and in their children during the first year of life. Univariate and multivariate models adjusted for HIV infection, parity, and age were estimated. Two-tailed P values ,.05 were considered statistically significant.
RESULTS
The study comprised 890 blood filter papers obtained at delivery from 454 placentas (104 with evidence of active P. falciparum infection on histological examination and 62 with evidence of submicroscopic infections) and 436 peripheral blood samples (86 of which were positive for P. falciparum on microscopic examination and 73 of which showed evidence of submicroscopic infections) of pregnant women enrolled in the IPTp trial [17] .
Among the 325 P. falciparum-positive samples, genotypes for msp-1/msp-2 and the 5 dhfr/dhps codons were finally obtained for 270 isolates (83%) (145 from placental blood specimens and 125 from peripheral blood specimens; Table 1 : mean density 6 SD, 11481.6 6 23862.9; P 5 .229). However, qPCR densities were significantly lower in SP recipients than in placebo recipients (P 5 .041 for peripheral blood infection and ,.001 for placental blood infections; Table 1 ). MOI of placental and peripheral blood infections was also lower in women who received SP than in those who received placebo, although the differences were not statistically significant (Table 1) . To take into account the interval between sample collection at delivery and the last SP dose, the analysis was stratified by early and late IPTp treatment (Figure 1 ). Placental q-mutants were significantly more prevalent in SP recipients (7 [50%] of 14) than in placebo recipients (6 [12%] of 52; P 5 .004) but only among women who received a late-IPTp intervention. In contrast, the prevalence of peripheral q-mutants was similar in SP (1 [7%] of 14) and placebo late recipients (4 [8%] of 51; P ..99). In both placental and peripheral infections, the prevalence of q-mutants was higher in HIV-positive women than in HIVnegative women who received late IPTp (Figure 1) . No difference was found by parity (P ..99 for peripheral and placental blood infections) or across age groups (P 5 .848 for peripheral and P 5 .794 for placental blood infections). The multivariate analysis (Table 2) confirmed that treatment and HIV status were independently associated with higher risk of placental quintuple infections among women who received late IPTp intervention. No difference in the prevalence of q-mutants was found by intervention, HIV status, parity, or age among women who received early IPTp in the univariate (Figure 1 ) or in the multivariate (Table 2) analyses.
The paired analysis (McNemar's test) of the 99 matched placental-peripheral blood infections from the same pregnant women at delivery showed that prevalence of q-mutants was higher in the placenta (7 
Effect of Q-Mutants on Maternal-Fetal Outcomes
There was no statistically significant association between the presence of q-mutants and parasite densities, placental inflammation, MOI, newborn weight, and hematocrit level of the mother at delivery and postpartum, of the cord blood, or of the children at 1 month of age (Table 3) . Similarly, no effect was found on the number of clinical malaria episodes in mothers during the postpartum period or in their children during the first year of life (Table 3) .
DISCUSSION
Understanding the shifting patterns of SP resistance in its role for IPTp is vital to inform antimalarial policies in countries in which malaria is endemic. The results of this study show that, as long as residual SP was expected to have been cleared from the blood at delivery (if last IPTp dose was taken beyond 2.5 months before delivery) [9] , the prevalence of placental and peripheral q-mutant parasites were similar in women who had received SP and those who had received placebo. However, IPTp was associated with an increase in q-mutant parasites in the placenta, but not in peripheral blood, when SP was expected to be present in blood (if last IPTp dose was taken within 2.5 months before delivery). Importantly, mutant infections were not associated with more-severe infections or higher malaria-related morbidity in mothers and their children.
This study shows that, although SP concentrations are expected to be uniform in the placenta and peripheral blood, the prevalence of highly drug-resistant parasites is higher in the placenta than in matched peripheral blood specimens. This observation cannot be explained by an increased selection of mutations in the placenta as a result of higher parasite densities [23] , because a similar prevalence of mutated parasites in the peripheral and placental blood would be expected, given the overlapping distribution of genotypes in both compartments [24] . Our data, rather, support a model wherein q-mutants selected by SP can multiply in the placenta, because local immunity, likely altered to support the fetal allograft [25] [26] [27] , clears parasites less effectively and therefore imposes less selective pressure on resistant parasites. In contrast, resistant parasites, with a deficient folate metabolism imposed by the mutations [28] , may be killed by a more effective systemic immunity in the peripheral blood. This theory is consistent with our other finding, that q-mutants are also more prevalent in HIV-positive women, for whom adaptive immunity to P. falciparum is systemically impaired [5] . Because Mozambican policy for antenatal care for HIVpositive women at the time of the study included nevirapine but not the antifolate cotrimoxazole, confounding by crossresistance is unlikely. We cannot discard, however, the possibility that folic acid supplementation, which is recommended to African pregnant women to prevent maternal anemia and which has been suggested to reduce clearance of P. falciparum by SP [29] , might have influenced development of SP resistance in parasites from the groups that we compared. Our findings, together with the lower prevalence of qmutants among pregnant women who received placebo as IPTp (16%), compared with that among children who also received placebo as IPTi (52%) [30] in the same area and period of time, support the notion that host immunity and fitness loss contribute importantly to the elimination of drug-resistant parasites [6, 31] . The current study shows that infections with q-mutant parasites are not associated with higher parasite densities or placental inflammation. This finding is in accordance with similar observations in the context of IPTi [30, 32] but contrasts with a recent report showing increased parasite densities and placental inflammation among Tanzanian women who received IPTp, an observation attributed to competitive facilitation [15] . The different findings could be explained if other genotypes, like mutations in codon dhps-581 [33] , were responsible for higher levels of parasite resistance. However, in contrast to that study [15] , this mutation was nearly absent from the parasite population infecting pregnant women from Manhic xa area. Alternatively, lack of randomization and self-reported IPTp use in the first study [15] might have created endogeneity bias if women who chose IPTp were those with increased susceptibility to highdensity malaria infections. Also, other mutations not assessed in our study might be associated with higher parasite densities in the placenta. Regardless of mutation status, SP was not found to increase parasitemias but, rather, was found to reduce qPCRdetected parasitemias and the MOI. Moreover, IPTp with SP has been shown to reduce the prevalence of peripheral and active placental infections [17] . Finally, this study showed that, as previously reported [12, 13] , q-mutants were not associated with poor maternal-fetal outcomes or higher incidences of malaria episodes in women at postpartum or their infants, which is consistent with the lack of an effect of the mutations on parasite densities. The results of this study suggest that the contribution of IPTp with SP to drug pressure at the population level is likely to be small. The IPTp-associated increase of q-mutant parasites in the placenta rapidly disappears after SP is expected to have been cleared from blood (2.5 months after drug intake), suggesting that these mutants are not competitive in the face of reinfection with other strains and that resistance will wane as active drug pressure decreases [28, 34] . A similar reduction in the prevalence of molecular markers of CQ resistance was observed in Malawi after CQ was abandoned as a first-line treatment [35] . Furthermore, the overall pressure exerted by SP given for IPTp is expected to be low, because pregnant women make up only 3% of the overall population of Manhic xa (as in similar areas) at a given time. Finally, as SP alone is no longer a first-line antimalarial drug in areas of endemicity, treatment of pregnant women who show symptomatic malaria with artemisinin-based combination therapies should reduce the spread of mutant parasites.
It can be concluded that SP given for IPTp selects for dhfr/ dhps mutant parasites in the placenta and in HIV-infected women, but only while residual plasma drug levels are present in blood. These results support the concept that impaired adaptive immune responses in the placenta [36] and in HIV-infected pregnant women [5] contribute to increased P. falciparum parasitemias [1, 37] . Importantly, mutant infections wane rapidly after SP is eliminated from blood and are not translated into more-severe infections or higher malaria-related morbidity in mothers and children. It is thus likely that IPTp with SP has only a subtle effect on SP resistance at the population level, especially in areas of endemicity, where competition from less-resistant parasites is intense and SP is not used as first-line therapy.
